{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:51:11Z","timestamp":1793767871036,"version":"4.6.1"},"reference-count":46,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2025,7,31]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                  <jats:italic>Mycoplasma pneumoniae<\/jats:italic> is a frequent cause of respiratory tract infections in both children and adults, responsible for up to 30% of community-acquired pneumonia cases in children. While many infected individuals remain asymptomatic, common symptoms include fever \u2013 which is typically short-lived \u2013 and a persistent cough, sometimes lasting weeks. Early identification of <jats:italic>M. pneumoniae<\/jats:italic> is crucial for effective management. However, distinguishing it from other viral or bacterial lower respiratory tract infections based on symptoms alone is unreliable due to the nonspecific clinical presentation.<\/jats:p>\n               <jats:p>Currently, the most accurate method for diagnosing <jats:italic>M. pneumoniae<\/jats:italic> is PCR testing, as traditional culture methods are slow and technically challenging. Paired serology testing is also used for diagnosis. It is important to evaluate locally available diagnostic resources. First-line treatment typically involves macrolide antibiotics, despite lack of robust data for their use. However, widespread use has contributed to increasing macrolide resistance, especially in Asia, prompting consideration of alternatives like fluoroquinolones and tetracyclines. In severe or treatment-resistant cases, additional therapies such as prednisolone, intravenous immunoglobulin or bronchoscopy may be used, although evidence supporting their routine application is limited.<\/jats:p>\n               <jats:p>Overall, clinical decisions should be individualised, guided by local transmission patterns, available diagnostics and emerging antibiotic resistance patterns.<\/jats:p>","DOI":"10.1183\/20734735.0046-2025","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:06:08Z","timestamp":1760450768000},"page":"250046","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["<i>Mycoplasma pneumoniae<\/i> respiratory tract infections in children: when and how to diagnose and treat"],"prefix":"10.1183","volume":"21","author":[{"given":"Lara","family":"Sharplin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7533-2315","authenticated-orcid":false,"given":"Vikas","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"2025101407050699000_21.4.250046.1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004875.pub5"},{"key":"2025101407050699000_21.4.250046.2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.4.697-728.2004"},{"key":"2025101407050699000_21.4.250046.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1984.03340310050022"},{"key":"2025101407050699000_21.4.250046.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.48.1.41"},{"key":"2025101407050699000_21.4.250046.5","doi-asserted-by":"publisher","DOI":"10.2217\/17460913.3.6.635"},{"key":"2025101407050699000_21.4.250046.6","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000171"},{"key":"2025101407050699000_21.4.250046.7","doi-asserted-by":"crossref","first-page":"101019","DOI":"10.1016\/j.lanmic.2024.101019","article-title":"Global spatiotemporal dynamics of Mycoplasma pneumoniae re-emergence after COVID-19 pandemic restrictions: an epidemiological and transmission modelling study","volume":"6","year":"2025","journal-title":"Lancet Microbe"},{"key":"2025101407050699000_21.4.250046.8","first-page":"ii1","article-title":"British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011","volume":"66: Suppl. 2","author":"Harris","year":"2011","journal-title":"Thorax"},{"key":"2025101407050699000_21.4.250046.9","doi-asserted-by":"crossref","first-page":"625","DOI":"10.21037\/tp-22-127","article-title":"Laboratory analysis of positive rate of Mycoplasma pneumoniae antibody among 53,273 children with respiratory tract infections in Xi'an from 2017 to 2020","volume":"11","author":"Meng","year":"2022","journal-title":"Transl Pediatr"},{"key":"2025101407050699000_21.4.250046.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405870"},{"key":"2025101407050699000_21.4.250046.11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3892\/etm.2024.12559","article-title":"Exploring the pathogenetic mechanisms of Mycoplasma pneumoniae (Review)","volume":"28","author":"Georgakopoulou","year":"2024","journal-title":"Exp Ther Med"},{"key":"2025101407050699000_21.4.250046.12","doi-asserted-by":"crossref","first-page":"1613760","DOI":"10.3389\/fmicb.2025.1613760","article-title":"Advances in adhesion-related pathogenesis in Mycoplasma pneumoniae infection","volume":"16","author":"Sun","year":"2025","journal-title":"Front Microbiol"},{"key":"2025101407050699000_21.4.250046.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0510644103"},{"key":"2025101407050699000_21.4.250046.14","doi-asserted-by":"crossref","first-page":"e159ms3491","DOI":"10.54905\/disssi.v28i154.e159ms3491","article-title":"The role of Mycoplasma pneumoniae in the pathogenesis of autoimmune diseases: mechanisms, complications, and therapeutic perspectives","volume":"28","author":"Gw\u00f3\u017ad\u017a-Broczkowska","year":"2024","journal-title":"Med Sci"},{"key":"2025101407050699000_21.4.250046.15","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00114-16"},{"key":"2025101407050699000_21.4.250046.16","first-page":"CD009175","article-title":"Clinical symptoms and signs for the diagnosis of Mycoplasma pneumoniae in children and adolescents with community-acquired pneumonia","volume":"10","author":"Wang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025101407050699000_21.4.250046.17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PEC.0000000000003338","article-title":"Clinical features and management strategies in children with Mycoplasma pneumoniae","volume":"41","author":"Garcia","year":"2025","journal-title":"Pediatr Emerg Care"},{"key":"2025101407050699000_21.4.250046.18","first-page":"855","article-title":"Clinical characteristics of pneumonia caused by Mycoplasma pneumoniae in children of different ages","volume":"11","author":"Lu","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"2025101407050699000_21.4.250046.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.06.022"},{"key":"2025101407050699000_21.4.250046.20","doi-asserted-by":"crossref","first-page":"10002","DOI":"10.7189\/jogh.12.10002","article-title":"A systematic review of the clinical features of pneumonia in children aged 5\u20139 years: implications for guidelines and research","volume":"12","author":"Kevat","year":"2022","journal-title":"J Glob Health"},{"key":"2025101407050699000_21.4.250046.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.032"},{"key":"2025101407050699000_21.4.250046.22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-10-48"},{"key":"2025101407050699000_21.4.250046.23","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamadermatol.2019.3602","article-title":"Frequency and clinical presentation of mucocutaneous disease due to Mycoplasma pneumoniae infection in children with community-acquired pneumonia","volume":"156","author":"Meyer Sauteur","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2025101407050699000_21.4.250046.24","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002171"},{"key":"2025101407050699000_21.4.250046.25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001444"},{"key":"2025101407050699000_21.4.250046.26","doi-asserted-by":"crossref","unstructured":"Meyer Sauteur PM , Panisova E , Bachmann LM , et al. Evaluation of IgM lateral flow assay as a screening tool for Mycoplasma pneumoniae infection in childhood pneumonia. J Clin Microbiol 2020; 58: e01498-20. doi:10.1128\/JCM.01498-20","DOI":"10.1128\/JCM.01498-20"},{"key":"2025101407050699000_21.4.250046.27","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2021200131"},{"key":"2025101407050699000_21.4.250046.28","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1148\/radiographics.21.1.g01ja10121","article-title":"Spectrum of clinical and radiographic findings in pediatric mycoplasma pneumonia","volume":"21","author":"John","year":"2001","journal-title":"Radiographics"},{"key":"2025101407050699000_21.4.250046.29","doi-asserted-by":"crossref","first-page":"659677","DOI":"10.3389\/fped.2021.659677","article-title":"Explore the predictive value of peripheral blood cell parameters in refractory Mycoplasma pneumoniae pneumonia in children over 6 years old","volume":"9","author":"Ling","year":"2021","journal-title":"Front Pediatr"},{"key":"2025101407050699000_21.4.250046.30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s12519-017-0014-9","article-title":"Effects of methylprednisolone or immunoglobulin when added to standard treatment with intravenous azithromycin for refractory Mycoplasma pneumoniae pneumonia in children","volume":"13","author":"Shan","year":"2017","journal-title":"World J Pediatr"},{"key":"2025101407050699000_21.4.250046.31","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1017\/S0950268824001134","article-title":"The predictive values of C-reactive protein-neutrophil to lymphocyte ratio for the risk of refractory Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study","volume":"152","author":"Chen","year":"2024","journal-title":"Epidemiol Infect"},{"key":"2025101407050699000_21.4.250046.32","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir531"},{"key":"2025101407050699000_21.4.250046.33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1961.03040150034009"},{"key":"2025101407050699000_21.4.250046.34","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2013-3729"},{"key":"2025101407050699000_21.4.250046.35","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s13063-024-08438-6","article-title":"A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study","volume":"25","author":"Meyer Sauteur","year":"2024","journal-title":"Trials"},{"key":"2025101407050699000_21.4.250046.36","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s12519-024-00831-0","article-title":"Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children","volume":"20","author":"Wang","year":"2024","journal-title":"World J Pediatr"},{"key":"2025101407050699000_21.4.250046.37","doi-asserted-by":"crossref","first-page":"001910","DOI":"10.1099\/jmm.0.001910","article-title":"Mycoplasma pneumoniae: not a typical respiratory pathogen","volume":"73","author":"Rowlands","year":"2024","journal-title":"J Med Microbiol"},{"key":"2025101407050699000_21.4.250046.38","doi-asserted-by":"crossref","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025101407050699000_21.4.250046.39","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10070-3"},{"key":"2025101407050699000_21.4.250046.40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1186\/s12879-021-06508-7","article-title":"Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis","volume":"21","author":"Ahn","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2025101407050699000_21.4.250046.41","doi-asserted-by":"crossref","first-page":"14860","DOI":"10.1038\/s41598-025-99537-0","article-title":"Treatment modalities for fever duration in children with Mycoplasma pneumoniae pneumonia","volume":"15","author":"Kang","year":"2025","journal-title":"Sci Rep"},{"key":"2025101407050699000_21.4.250046.42","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12890-024-02996-w","article-title":"Predictive value of bronchoscopy combined with CT score for refractory Mycoplasma pneumoniae pneumonia in children","volume":"24","author":"Lu","year":"2024","journal-title":"BMC Pulm Med"},{"key":"2025101407050699000_21.4.250046.43","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41390-021-01874-z","article-title":"The role of flexible bronchoscopy in children with Mycoplasma pneumoniae pneumonia","volume":"93","author":"Wang","year":"2023","journal-title":"Pediatr Res"},{"key":"2025101407050699000_21.4.250046.44","doi-asserted-by":"crossref","first-page":"e20121","DOI":"10.1097\/MD.0000000000020121","article-title":"Efficacy and safety of azithromycin combined with glucocorticoid on refractory Mycoplasma pneumoniae pneumonia in children: a PRISMA-compliant systematic review and meta-analysis","volume":"99","author":"Qiu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025101407050699000_21.4.250046.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1204664"},{"key":"2025101407050699000_21.4.250046.46","doi-asserted-by":"publisher","DOI":"10.1007\/s002470050286"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0046-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:06:26Z","timestamp":1760450786000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0046-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,14]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1183\/20734735.0046-2025"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0046-2025","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}